TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today provided an update on its solid tumor and heme malignancies clinical programs.
- “We continue to make meaningful progress across both our solid tumor and heme malignancies Phase 1 clinical programs.
- This should allow for rapid enrollment into the treatment protocol over the course of the year,” said Gavin MacBeath, Ph.D., Chief Executive Officer.
- Phase 1 solid tumor clinical study has been initiated; first three patients expected to be dosed in early May 2024.
- Completion of Phase 1 enrollment and reporting of one-year clinical and translational data on initial patients is anticipated in the second half of 2024.